revolutionizing vascular access

« aXess » restorative graft

Aditlys develops a novel vascular access graft using a unique material technology

Aditlys’ grafts utilize a porous material made of a patented biodegradable polymer.

Once implanted, the device triggers a unique process of tissue restoration, called Endogenous Tissue Restoration, or ETR, that eventually leads to the resorption of the graft and its replacement by an actual blood vessel.

With this particular approach, Aditlys is expecting to reduce the complications faced routinely by the patients undergoing hemodialysis. The ambition is to define a new standard of care for vascular access that will improve the quality of life of millions of people.

Early stage developments are done and the project is currently entering its final phase.
Aditlys is bringing a game changing technology in a market estimated to be worth a few billion dollars.

Technology

  • Hemodialysis
  • Current Vascular Access
  • Etr Technology

PLEASE SELECT ONE OF THE ABOVE OPTIONS TO LEARN MORE

Choose an item above to learn more

Team

Silvere Luquin - CEO

SILVERE LUCQUIN | CEO

Silvere Lucquin is a medtech entrepreneur and has a background in business and engineering. Prior to Aditlys, Silvere contributed to found CorWave, a fast-growing start-up company based out of Paris and developing innovative cardiac assist devices.

As CorWave’s employee number one, Silvere has been involved in various parts of the project, including recruiting, fund raising and R&D project management.

Silvere notably won the 2016 edition of the Worldwide Innovation Challenge (“Concours Mondial Innovation”) in the “Start-up, Silver economy” category.

Silvere started his career at SpineVision, an SME developing and commercializing innovative spine implants. He holds an MSc from Ecole Polytechnique in France and Imperial College of London in the UK as well as an MBA from INSEAD.

Luke Burke - Head of RnD

LUKE BURKE | HEAD OF R&D

Luke Burke is the lead R&D expert for the Aditlys project and has been managing development of devices since their inception. Luke brings over 6 years of R&D experience in the fields of regenerative medicine and tissue engineering, including a PhD obtained from Swansea University (UK) on the technique of electrospinning and its application to tissue engineering.

Prior to joining Aditlys, Luke worked as a Senior R&D Engineer for Xeltis B.V., where he worked on developing manufacturing processes and lead research projects for new applications of the Xeltis technology platform. Luke started his career at Avectas Life Sciences in Dublin, ROI on bespoke engineering projects for institutions including Harvard Medical, Brigham & Women's Hospital, and Massachusetts Institute of Technology. Luke holds a PhD in chemical engineering and has authored a range of articles in peer-reviewed scientific journals.

Marc Sola - Chairman

MARC SOLA | CHAIRMAN OF THE BOARD

As the chairman of Aditlys, Marc Sola brings over 20 years of experience as an entrepreneur. Marc started his first company at the age of 20 and has since founded, or co-founded, a number of businesses in different fields and multiple countries.

Marc holds a Masters of Law degree from the University of Zurich and serves on the board of various companies. Mr. Sola is a sought after speaker at international investment, asset protection and estate planning conferences worldwide. Furthermore, he has published a variety of professional articles and co-authored the book, The Insured Portfolio, published by John Wiley & Sons (2010). He is a member of YPO (Young Presidents Organization), Zurich Chapter.

Laurent Grandidier - Director

LAURENT GRANDIDIER | DIRECTOR

Laurent Grandidier is a Director on the board of Aditlys and a Medtech entrepreneur who brings over 15 years of experience as a business leader in the industry. Laurent is the CEO of Xeltis, a fast-growing company developing heart valves using the ETR technology. For 7 years, Laurent has transformed the company from a small research entity into one of the most promising medical device companies globally. In 2015, he notably led an oversubscribed series B financing round of over $30 million.

Prior to Xeltis, Laurent occupied various leadership positions in companies such as Endosense, Guidant/Boston Scientific and Teleflex Medical. Laurent is also co-founder of one of France’s first social venture funds, Investir&+, where he currently sits on the supervisory board. He is a board member of the Frédérique Constant Foundation, supporting pediatric clinical and research centers for treatment of children and young people with heart diseases in countries where such facilities are unavailable.

Contact us

revolutionizing revolutionizing revolutionizing revolutionizing

Baarerstrasse 137
6302 Zug
Switzerland

De Lismortel 31
5612AR Eindhoven
The Netherlands

Station F,
55 Boulevard Vincent Auriol
75013 Paris
France

Your message has been sent. Thank you!
Submit